{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2243.49","value":"2650"},{"groupId":"OG001","spread":"258.09","value":"247.5"},{"groupId":"OG002","spread":"4775.11","value":"3531.5"},{"groupId":"OG003","spread":"324.50","value":"430"},{"groupId":"OG004","spread":"124.90","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"description":"Mean concentration of VEGF2 in peripheral blood sample.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive oral sorafenib 105 mg/m\\^2 every 12 hours.","id":"OG000","title":"Part A: Refractory Solid Tumors: BAY 43-9006 105 mg/m^2"},{"description":"Patients receive oral sorafenib 130 mg/m\\^2 every 12 hours.","id":"OG001","title":"Part A: Refractory Solid Tumors: BAY 43-9006 130 mg/m^2"},{"description":"Patients receive oral sorafenib 150 mg/m\\^2 every 12 hours.","id":"OG002","title":"Part A: Refractory Solid Tumors: BAY 43-9006 150 mg/m^2"},{"description":"Patients receive oral sorafenib 200 mg/m\\^2 every 12 hours.","id":"OG003","title":"Part A: Refractory Solid Tumors: BAY 43-9006 200 mg/m^2"},{"description":"Patients receive oral sorafenib 200 mg/m\\^2 every 12 hours.","id":"OG004","title":"PK Cohort Expanded: BAY 43-9006 200 mg/m^2"}],"paramType":"MEAN","populationDescription":"Data were not collected for Part A: 250 mg/m\\^2, Part B:150 mg/m\\^2, Part B: 200 mg/m\\^2, and Part C:150 mg/m\\^2","reportingStatus":"POSTED","timeFrame":"28 days","title":"Mean Concentration of VEGF2","type":"SECONDARY","unitOfMeasure":"cells/ml"}